The vascular disrupting agents market is expected to reach USD 23 million in 2021 and anticipated to grow at a CAGR of 65% during the forecast period 2021-2030.

Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts towards developing innovative anticancer therapies tailored for these types of cancers. Over the past five years, the United States Food and Drug Administration (USFDA) has approved over 100 drugs for diverse cancer treatments. Despite these advancements, the increasing global exposure to various carcinogens and risk factors necessitates the development of more targeted and potent drugs or therapies to effectively combat this complex and life-threatening disease. The rapid growth of malignant cell masses that characterize solid tumors emphasizes the critical role of angiogenesis and adequate blood supply in sustaining the tumor population. Consequently, targeting tumor vasculature remains a compelling and promising approach in therapeutic pursuits. Vascular disrupting agents (VDAs) are interventions aimed at established tumor vasculature, thereby disrupting blood flow to cancerous tissues.

Currently, several small molecule VDAs are either under development or have been developed to address various oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma, and ovarian cancer. Additionally, combination therapies that integrate VDAs with conventional chemotherapy, radiation therapy, and radioimmunotherapy have shown significant clinical responses in various animal models.

Significantly, the advancements in this field receive substantial support from the National Institutes of Health, with research grants totaling USD 95 million disbursed since 2016. Driven by promising clinical research outcomes, this specialized yet burgeoning domain is poised for robust market growth in the foreseeable future. Early entrants are expected to gain a competitive edge as pioneers in this evolving landscape.

Report Coverage
? Examine the vascular disrupting agents market by categorizing it based on indications, therapeutic areas, molecules, therapy types, administration routes, and geographical regions.
? Analyze market growth factors like drivers, restraints, opportunities, and challenges.
? Evaluate potential market advantages and obstacles, focusing on the competitive landscape for leading players.
? Forecast revenue for market segments across six major regions.
? Assess the current landscape of vascular disrupting agents, detailing developmental stages of product candidates, therapeutic areas, molecule types, therapy types, and administration routes. Provide a comprehensive list of companies involved in this development, considering establishment year, company size, and headquarters location.
? Present detailed profiles of prominent market players based on their pipeline volume, including company overview, financial information, lead drug candidates’ descriptions, development status, indications, mode of action, therapy type, recent developments, and future forecasts.
? Conduct an in-depth analysis of completed, ongoing, and planned clinical studies on vascular disrupting agents. Highlight trends in trial status, patient population, regional distribution, molecule types, developmental phases, study designs, leading industry and non-industry players, focus, and key indications.
? Review over 750 peer-reviewed scientific articles on vascular disrupting agents published between 2016 and January 2021. Analyze trends in publication years, emerging focus areas, keywords, indications, therapeutic areas, research journals, and notable authors.
? Analyze grants awarded to research institutes between 2016 and January 2021 related to vascular disrupting agents. Parameters include the year of award, amount, administering institute, support period, grant type, purpose, activity code, focus areas, popular departments, recipient organization types, highlighting popular recipients, program officers, and regional distribution.
? Compile a list of key opinion leaders (KOLs) in the vascular disrupting agents market. Assess their prominence and activity using a 2x2 matrix representation. Create a world map indicating the locations of eminent scientists/researchers. Evaluate KOL expertise based on publications, citations, clinical trial participation, affiliations, and professional networks available on ResearchGate.

Key Market Companies
? AGC Biologics
? Avid Bioservices
? Bionomics
? Mateon Therapeutics
? Myrexis
? VBL Therapeutics